# Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

> **NCT00575068** · PHASE1,PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 42 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** IDEC-114

## Key facts

- **NCT ID:** NCT00575068
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2002-09
- **Final completion:** 2010-11
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2012-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00575068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00575068, "Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00575068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*